Radspherin

Oncoinvent's Phase 1 trial of Radspherin® demonstrates only 10% recurrence rate at 18-month follow-up in patients with platinum-sensitive recurrent ovarian cancer, compared to expected 40% with standard care.

Oncoinvent has completed patient recruitment for the safety lead-in phase of its Phase 2 trial evaluating Radspherin®, a novel alpha-radiation therapy for peritoneal metastases from ovarian cancer.

Oncoinvent announced positive interim results from Phase 1/2a studies of Radspherin® for peritoneal carcinomatoses, showing potential for local control in the peritoneum.

Phase 1/2a study of Radspherin® demonstrates encouraging safety and efficacy in colorectal cancer patients with peritoneal metastases.

Oncoinvent has dosed the first patient in a Phase 2 clinical trial of Radspherin for peritoneal carcinomatosis originating from ovarian cancer.